PMN-MDSCs Are Responsible for Immune Suppression in Anti-PD-1 Treated TAP1 Defective Melanoma

Overview

Journal Clin Transl Oncol

Date 2025 Jan 18

PMID 39825997

Authors

Xiao Zhang

Kaijun Sun

Bingzheng Zhong

Likun Yan

Pengrui Cheng

Qiang Wang

Affiliations

Soon will be listed here.

Abstract

Introduction: The transporter associated with antigen processing (TAP) is a key component of the classical HLA I antigen presentation pathway. Our previous studies have demonstrated that the downregulation of TAP1 contributes to tumor progression and is associated with an increased presence of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. However, it remains unclear whether the elevation of MDSCs leads to immune cell exhaustion in tumors lacking TAP1. In this study, we established mouse models of tumors with TAP1 deficiency, and we employed PMN-MDSC depletion to investigate their impact on the immune microenvironment within the tumors. We found that MDSC depletion significantly altered the immune-suppressive effects of TAP1-deficient tumor when anti-PD-1 treatment was administered. Targeting PMN-MDSC may be a promising therapeutic strategy for the treatment of tumors with TAP1 deficiency during ICB treatment.

Methods: Immunohistochemistry (IHC) was conducted to assess TAP1 expression in mouse melanoma tissues. Ly6G, F4/80, and NKp46 markers were detected in B16 parental and TAP1 knockout tissues, respectively. To enhance anti-tumor immunity, hyperthermia-treated B16F10 WT cell suspension was injected prior to tumor cell introduction. Subsequently, we established B16F10 TAP1 knockout and WT melanoma mouse models. Tumors were collected, and the immune microenvironment was monitored accordingly. Anti-Ly6G antibody was administered to deplete polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). Finally, flow cytometry analysis for immune infiltration, quantitative PCR for cytokine levels, and immunofluorescence assays were performed to analyze the immune response.

Results: The level of Ly6G+ cell infiltration was significantly higher in samples exhibiting low TAP1 expression, while no differences were observed in the infiltration of F4/80+ cells or NKp46+ cells. Furthermore, the immune-suppressive effects associated with PMN-MDSCs were reversed following their elimination; this resulted in an increase in CD8+ T cells and a higher ratio of CD8+ T cells to Tregs, while the infiltration of innate immune cells remained unaffected. Functional markers of these immune cells indicated an active anti-tumoral immune response following the removal of PMN-MDSCs. Quantitative PCR analysis indicated elevated levels of TNF-α and IL-6, accompanied by decreased levels of TGF-β in the tumor microenvironment of TAP1.

Conclusions: Our data indicate that myeloid-derived suppressor cells (PMN-MDSCs) play an essential role in creating a tumorigenic immune microenvironment in TAP1 knockout tumors. Therefore, targeting PMN-MDSCs may become a promising therapeutic strategy for the treatment of tumors with TAP1 deficiency during ICB treatment.

References

Havel J, Chowell D, Chan T . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019; 19(3):133-150. PMC: 6705396. DOI: 10.1038/s41568-019-0116-x. View

He X, Xu C . Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020; 30(8):660-669. PMC: 7395714. DOI: 10.1038/s41422-020-0343-4. View

Binnewies M, Roberts E, Kersten K, Chan V, Fearon D, Merad M . Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018; 24(5):541-550. PMC: 5998822. DOI: 10.1038/s41591-018-0014-x. View

Tu Z, Li K, Ji Q, Huang Y, Lv S, Li J . Pan-cancer analysis: predictive role of TAP1 in cancer prognosis and response to immunotherapy. BMC Cancer. 2023; 23(1):133. PMC: 9912572. DOI: 10.1186/s12885-022-10491-w. View

Dhatchinamoorthy K, Colbert J, Rock K . Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021; 12:636568. PMC: 7986854. DOI: 10.3389/fimmu.2021.636568. View

Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L . Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007; 13(7):828-35. PMC: 2135607. DOI: 10.1038/nm1609. View

Schadendorf D, van Akkooi A, Berking C, Griewank K, Gutzmer R, Hauschild A . Melanoma. Lancet. 2018; 392(10151):971-984. DOI: 10.1016/S0140-6736(18)31559-9. View

Samstein R, Lee C, Shoushtari A, Hellmann M, Shen R, Janjigian Y . Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019; 51(2):202-206. PMC: 6365097. DOI: 10.1038/s41588-018-0312-8. View

Tobin R, Jordan K, Robinson W, Davis D, Borges V, Gonzalez R . Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018; 63:282-291. PMC: 6134177. DOI: 10.1016/j.intimp.2018.08.007. View

10.

Chen X, Pan X, Zhang W, Guo H, Cheng S, He Q . Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses. Acta Pharm Sin B. 2020; 10(5):723-733. PMC: 7276686. DOI: 10.1016/j.apsb.2019.09.006. View

11.

Barry S, Gabrilovich D, Sansom O, Campbell A, Morton J . Therapeutic targeting of tumour myeloid cells. Nat Rev Cancer. 2023; 23(4):216-237. DOI: 10.1038/s41568-022-00546-2. View

12.

Sui H, Dongye S, Liu X, Xu X, Wang L, Jin C . Immunotherapy of targeting MDSCs in tumor microenvironment. Front Immunol. 2022; 13:990463. PMC: 9484521. DOI: 10.3389/fimmu.2022.990463. View

13.

Tomela K, Pietrzak B, Galus L, Mackiewicz J, Schmidt M, Mackiewicz A . Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy. Cells. 2023; 12(5). PMC: 10000540. DOI: 10.3390/cells12050789. View

14.

Cornel A, Dunnebach E, Hofman D, Das S, Sengupta S, van den Ham F . Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch. J Immunother Cancer. 2022; 10(12). PMC: 9756225. DOI: 10.1136/jitc-2022-005002. View

15.

Sun S, Angell C, Savardekar H, Sundi D, Abood D, Benner B . BTK inhibition potentiates anti-PD-L1 treatment in murine melanoma: potential role for MDSC modulation in immunotherapy. Cancer Immunol Immunother. 2023; 72(11):3461-3474. PMC: 10592087. DOI: 10.1007/s00262-023-03497-1. View

16.

Zhang X, Sabio E, Krishna C, Ma X, Wang J, Jiang H . Qa-1 Modulates Resistance to Anti-PD-1 Immune Checkpoint Blockade in Tumors with Defects in Antigen Processing. Mol Cancer Res. 2021; 19(6):1076-1084. PMC: 8178214. DOI: 10.1158/1541-7786.MCR-20-0652. View

17.

Wu Y, Yi M, Niu M, Mei Q, Wu K . Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022; 21(1):184. PMC: 9513992. DOI: 10.1186/s12943-022-01657-y. View

18.

Del Val M, Anton L, Ramos M, Munoz-Abad V, Campos-Sanchez E . Endogenous TAP-independent MHC-I antigen presentation: not just the ER lumen. Curr Opin Immunol. 2020; 64:9-14. DOI: 10.1016/j.coi.2019.12.003. View

19.

Alspach E, Lussier D, Schreiber R . Interferon γ and Its Important Roles in Promoting and Inhibiting Spontaneous and Therapeutic Cancer Immunity. Cold Spring Harb Perspect Biol. 2018; 11(3). PMC: 6396335. DOI: 10.1101/cshperspect.a028480. View

20.

Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X . Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24(10):1550-1558. PMC: 6487502. DOI: 10.1038/s41591-018-0136-1. View